Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease

Wang, Xiaofang; Zhao, Xiaoyan; Li, Ling; Yao, Hai-Mu; Jiang, Yan; Zhang, Jinying

doi:10.1016/j.hlc.2015.10.012

Cited by 43 publications

(35 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistently, Seeger et al (24) found a negative relationship between Vaspin and CRP in patients on chronic hemodialysis and Kadoglou et al (15) found an independent association of reduced Vaspin with increased hs-CRP and Visfatin levels suggesting a protective mechanism. Previous studies also, have indicated that CRP is an independent risk factor for atherosclerotic cardiovascular disease (25).…”

Section: Discussionmentioning

confidence: 92%

Effect of rosuvastatin on serum levels of vaspin and visfatin in patients with CAD

Werida¹,

Khedr²,

El‐Sisi³

et al. 2018

Curr Res Cardiol

View full text Add to dashboard Cite

METHODS: 80 patients who underwent coronary angiography due to symptoms of stable angina were enrolled in the study. 40 patients received Rosuvastatin 20 mg/day was compared to another 40 patients, as a control group, who refused statin treatment and preferred lifestyle modifications intervention. Main outcome measure: Clinical parameters, lipid profile, troponin I, high-sensitivity C-reactive protein (hs-CRP), Vaspin and Visfatin levels were assayed at the beginning and after 3 months. CAD severity was assessed by the Gensini score. RESULTS:Rosuvastatin administration considerably ameliorated most lipid parameters. Moreover, a significant increase of Vaspin and decrease of Visfatin concentrations (p<0.001) after Rosuvastatin treatment were observed (from 2.81 ± 0.74 ng/ml to 4.26 ± 0.76 ng/ml, from 4.62 ± 0.76 to 3.13 ± 0.98 respectively). There was a negative correlation between Vaspin and the Gensini score and positive correlation between Visfatin and Gensini score (r=-0.18 and r=0.19, p=0.05, respectively). CONCLUSION:Rousvastatin treatment reduces serum visfatin and increase serum vaspin levels in CAD patients. Those effects of Rousvastatin are of clinical importance.

show abstract

Section: Discussionmentioning

confidence: 92%

Effect of rosuvastatin on serum levels of vaspin and visfatin in patients with CAD

Werida¹,

Khedr²,

El‐Sisi³

et al. 2018

Curr Res Cardiol

View full text Add to dashboard Cite

show abstract

“…IMPROVE‐IT study was a large‐scale trial with 18,144 cases and a follow‐up period of 6 years. Trials enrolled high‐risk patients suffering from cardiovascular diseases, chronic kidney disease, peripheral arterial disease, and familial hypercholesterolemia . Across all studies 93% of patients had experienced acute coronary syndrome .…”

Section: Resultsmentioning

confidence: 99%

“…Four studies did not employ patient and clinician blinding . Six of the eight trials lost over 10% of patients to follow‐up for at least one clinically important outcome.…”

Section: Resultsmentioning

confidence: 99%

Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient‐important outcomes

Fei

Guyatt

Alexander

et al. 2017

Evaluation Clinical Practice

View full text Add to dashboard Cite

Ezetimibe is widely used in combination with statins to reduce low-density lipoprotein. We sought to examine the impact of ezetimibe when added to statins on patient-important outcomes. Medline, EMBASE, CINAHL, and CENTRAL were searched through July, 2016. Randomized controlled trials (RCTs) of ezetimibe combined with statins versus statins alone that followed patients for at least 6 months and reported on at least one of all-cause mortality, cardiovascular deaths, non-fatal myocardial infarctions (MI), and non-fatal strokes were included. Pairs of reviewers extracted study data and assessed risk of bias independently and in duplicate. Quality of evidence was assessed using the GRADE approach. We conducted a narrative review with complementary subgroup and sensitivity analyses. IMPROVE-IT study enrolled 93% of all patients enrolled in the 8 included trials. Our analysis of the IMPROVE-IT study results showed that in patients at high risk of cardiovascular events, ezetimibe added to statins was associated with i) a likely reduction in non-fatal MI (17 fewer/1000 treated over 6 years, moderate certainty in evidence); ii) a possible reduction in non-fatal stroke (6 fewer/1000 treated over 6 years, low certainty); iii) no impact on myopathy (moderate certainty); iv) potentially no impact on all-cause mortality and cardiovascular death (both moderate certainty); and v) possibly no impact on cancer (low certainty). Addition of ezetimibe to moderate-dose statins is likely to result in 17 fewer MIs and possibly 6 fewer strokes/1000 treated over 6 years but is unlikely to reduce all-cause mortality or cardiovascular death. Patients who place a high value on a small absolute reduction in MI and are not adverse to use of an additional medication over a long duration may opt for ezetimibe in addition to statin therapy. Our analysis revealed no increased specific harms associated with addition of ezetimibe to statins.

show abstract

“…Az ezetimibbel a 2002-ben történt bevezetése óta számos vizsgálatot végeztek, ezek közül a fentebb részletezett IMPROVE-IT hozott érté-kes evidenciákat: a szer hatékonyan csökkenti a cardiovascularis rizikót, 21%-kal csökkentve az ischaemiás stroke bekövetkeztének esélyét is [27]. Az 50% feletti LDL-C-szint-csökkenést, emellett az ezetimib haté-konyságát támasztotta alá a coronariaplakk-regresszió-ban több vascularis ultrahanggal elvégzett vizsgálat is [29,30].…”

Section: Az Ldl-koleszterin-szint Csökkentésének úJ Irányvonalaiunclassified

Lipidek és az agyérbetegség – Új lehetőségek az LDL-koleszterin-szint csökkentésére

et al. 2016

View full text Add to dashboard Cite

A stroke világszerte a harmadik leggyakoribb halálok, a szívinfarktus és a daganatos betegségek után, funkcionális kimenetele pedig valamennyi betegség közül a legrosszabb. A koleszterin, különösen az LDL-C-szint kulcsszerepet játszik az érelmeszesedésben, a plakkok kialakulásában. Az elmúlt években bebizonyosodott, hogy az LDL-C-szint növekedésével arányosan emelkedik a cerebrovascularis betegségek incidenciája és halálozása. A statinterápia egyér-telműen csökkenti a stroke-rizikót, de a más módszerekkel elért lipidszintcsökkentő kezelésnek eddig nem volt igazoltan szignifikáns hatása. A magasabb dózisú statinkezelés preventív hatása egyértelmű, ugyanakkor az ilyen dózis alkalmazása fokozott óvatosságot igényel korábbi intracerebralis vérzést elszenvedett betegeknél, és kockáztathatjuk az új keletű diabetes kialakulását is. A közelmúltban közzétett IMPROVE-IT vizsgálat elsőként igazolta, hogy a statinterápia mellé adott nem statin típusú ezetimibbel az LDL-C-szint tovább csökkenthető, ezzel párhuzamosan tovább mérséklődik a cardio-és cerebrovascularis események incidenciája, a mellékhatások számának növekedése nélkül. Ezek az eredmények újra megerősítették a minél nagyobb mértékű LDL-C-szint-csökkentés jelentőségét. A statin-ezetimib kombináció révén a célértékek elérése alacsony és közepes statindózissal is lehetséges, csökkentve ezáltal a magas dózisú statinkezelés mellékhatásainak veszélyét. Orv. Hetil., 2016Hetil., , 157(52), 2059Hetil., -2065 Kulcsszavak: LDL-koleszterin, stroke, statinok, ezetimib Lipids and cerebrovascular disease -New therapeutic options in lowering LDL-cholesterolStroke is the third most common cause of death worldwide following myocardial infaction and malignancies, furthermore, its functional outcome is the worst of all conditions. Cholesterol, especially LDL-cholesterol plays a key role in the formation of atherosclerotic plaques. It has been verified recently that escalating incidence and mortality of cerebrovascular diseases are proportional to increased levels of LDL-cholesterol. Statin therapy undeniably reduces the risk of stroke, however other methods for decreasing lipid levels have not been proved significantly effective. Preventive effect of high-dose statin treatment is without doubt, although administration of such high dosage might require special precautions for patients with prior intracerebral hemorrhage and it also risks development of incident diabetes. The recently published IMPROVE-IT study is the first to prove that the addition of ezetimibe as a nonstatin type drug, to statin treatment contributes to further reduction of LDL-cholesterol. The combination treatment results in additional decrease in the incidence and mortality of cerebrovascular events, without any expansion in the number or adverse effects. These results confirm the importance of any further reduction of LDL-cholesterol levels. Achieving target values with statin-ezetimibe combination allows administration of low to moderate dose of statin, which decreases risks of adverse effects related to hig...

show abstract

Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease

Cited by 43 publications

References 15 publications

Effect of rosuvastatin on serum levels of vaspin and visfatin in patients with CAD

Effect of rosuvastatin on serum levels of vaspin and visfatin in patients with CAD

Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient‐important outcomes

Lipidek és az agyérbetegség – Új lehetőségek az LDL-koleszterin-szint csökkentésére

Contact Info

Product

Resources

About